Epizyme’s Tazemetostat Gains US FDA Panel Nod For Accelerated Approval In Epithelioid Sarcoma

FDA Advisory Committee Feature image
Oncologic Drugs Advisory Committee voted unanimously that tazemetostat's benefits outweigh its risks.

More from US FDA Performance Tracker

More from Regulatory Trackers